Drug Profile
Tonabacase - iNtRON Biotechnology
Alternative Names: LSVT-1701; N-Rephasin® SAL200; SAL200Latest Information Update: 02 Nov 2023
Price :
$50
*
At a glance
- Originator iNtRON biotechnology
- Developer iNtRON Biotechnology; Seoul National University Hospital
- Class Antibacterials; Coliphages; Endolysins; Endopeptidases; Proteins
- Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Methicillin-resistant Staphylococcus aureus infections
- No development reported Vancomycin-resistant Staphylococcus aureus infections
Most Recent Events
- 31 Oct 2023 Basilea Pharmaceutica plans a phase II trial for Methicillin-resistant Staphylococcus aureus infections in 2025
- 30 Oct 2023 Basilea Pharmaceutica entered into an exclusive license agreement for tonabacase from iNtRON Biotechnology
- 28 Jul 2022 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in South Korea (Intranasal)